Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement

Core Viewpoint - Moderna's stock surged after settling a patent dispute with Arbutus Biopharma for $950 million, alleviating concerns over potential liabilities that could have reached $5 billion [1][1][1] Group 1: Settlement Details - The settlement involves a one-time payment of $950 million to Arbutus and Genevant Sciences, with no future royalties owed [1][1] - Moderna plans to appeal to the Federal Circuit court, claiming immunity as a government contractor; if unsuccessful, it may incur an additional payment of up to $1.3 billion within 90 days [1][1] - The settlement resolves all litigation related to Moderna's Covid vaccines, including Spikevax and mResvia, and addresses future litigation for next-generation vaccines mNexspike and mCombriax [1][1] Group 2: Financial Implications - Following the settlement, Moderna expects to end the year with $4.5 billion to $5 billion in cash and equivalents [1][1] - Analysts view the settlement as a positive development, reducing potential liquidity concerns and allowing Moderna to focus on upcoming late-stage oncology trials expected in 2026 [1][1] Group 3: Stock Performance - Moderna's stock rose 16% to close at $57.82 after the settlement announcement [1][1] - The stock has experienced volatility, previously rising 87% to a peak of $55.20 on January 22, then dropping 34% by February 11, before rebounding [1][1] - The stock currently holds a strong IBD Digital Relative Strength Rating of 97 out of a possible 99, indicating it ranks in the top 3% of all stocks for 12-month performance [1][1]